The invention relates to therapeutic agents for use in the prevention or treatment of Alzheimers disease. In particular the invention relates to use of inhibitors of cell cycle re-entry and progression to the G1/S transition or inhibitors of progression of the cell cycle through the G1/S transition point in the prevention or treatment of Alzheimers disease.
